Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Théo de Witte, Stefano Guidi et al.|Journal of Clinical Oncology|2017Cited by 248
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElisabetta Sauta, Matteo Giovanni Della Porta, Marie Robin et al.|Journal of Clinical Oncology|2023Cited by 109
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic SyndromesCristina Astrid Tentori, Olivier Nibourel, Caterina Gregorio et al.|Journal of Clinical Oncology|2024Cited by 39
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)Cristina Astrid Tentori, Najla H. Al Ali, Caterina Gregorio et al.|Blood|2023Cited by 5
Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic SyndromesElisabetta Sauta, Matteo Giovanni Della Porta, Marie Robin et al.|Blood|2022Cited by 4